Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11β-methyl nortestosterone dodecylcarbonate
- Development stage
- Phase 1
- Lead developer
- National Institute of Child Health and Human Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
11β-methyl nortestosterone dodecylcarbonate (11β-MNTDC) is an experimental, orally active synthetic androgen and potential male hormonal contraceptive. It is a dodecylcarbonate ester and prodrug of 11β-methyl-19-nortestosterone (MENT), a potent androgen that is not susceptible to 5α-reduction. 11β-MNTDC acts as a dual agonist at the androgen receptor (AR) and the progesterone receptor (PR). This combined activity suppresses the hypothalamic-pituitary-gonadal axis, leading to a significant reduction in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which ultimately inhibits testicular testosterone production and spermatogenesis. Developed by the Population Council and the National Institute of Child Health and Human Development (NICHD), 11β-MNTDC is designed to provide androgen replacement while maintaining contraceptive efficacy, with a potentially improved safety profile regarding the prostate compared to testosterone.
- Other names
- 11β-methyl-19-nortestosterone 17β-dodecylcarbonate11-beta-methyl-19-nortestosterone dodecylcarbonate
02
Targets
AR (Adrenergic receptors)PR (Progesterone receptor)
Beyond the preview
Go deeper on 11β-methyl nortestosterone dodecylcarbonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11β-methyl nortestosterone dodecylcarbonate.